Previous 10 | Next 10 |
home / stock / gild / gild articles
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 150 points on Monday. The Dow traded up 0.41% to 38,018.2...
Gilead Sciences Inc (NASDAQ:GILD) said its Phase 3 EVOKE-01 study did not meet its primary endpoint of overall survival (OS) in previously tre...
The Federal Reserve is driving the market bus. Rate cut expectations have been re-drawn, and the “buy everything” sentiment that powere...
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 5.26% on an annualized basis producing an average annual return...
BofA Securities downgraded Bristol-Myers Squibb & Co (NYSE: BMY), noting that initially, the analyst believed that Bristol's...
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 5.22% on an annualized basis producing an average annual return...
Gilead Sciences Inc (NASDAQ: GILD) announced on Thursday that it has purchased 15 million shares of HOOKIPA Pharma Inc (NASDAQ: HOOK...
RedHill Biopharma Ltd (NASDAQ: RDHL) says opaganib and RHB-107 (upamostat) demonstrated robust synergistic effects when combined individually ...
Gilead Sciences Inc (NASDAQ: GILD) announced an agreement with Compugen Ltd (NASDAQ: CGEN) to license its pre-clinical antibody prog...
News, Short Squeeze, Breakout and More Instantly...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2024 financial results and guidance will be released on Thursday, August 8, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’...
– New 5-Year Clinical and Real-World Data Reinforce Biktarvy ® as a Long-Term Treatment Option for a Diverse Range of People with HIV, Including Those with Comorbidities – – Investigational, Once-Daily, Once-Weekly and Twice-Yearly Dosing Frequenc...
– PURPOSE 1 Data Showed Zero Infections and 100% Efficacy and Superiority of Lenacapavir to Background HIV Incidence and Daily Truvada ® for PrEP – – If Approved, Lenacapavir Would be the First and Only Twice-Yearly PrEP Choice and Could Address C...